Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Molecular Characterization of Renal Cell Carcinoma: A Potential Three-MicroRNA Prognostic Signature.

Lokeshwar SD, Talukder A, Yates TJ, Hennig MJP, Garcia-Roig M, Lahorewala SS, Mullani NN, Klaassen Z, Kava BR, Manoharan M, Soloway MS, Lokeshwar VB.

Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):464-472. doi: 10.1158/1055-9965.EPI-17-0700. Epub 2018 Feb 12.

PMID:
29440068
2.

Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets.

Morera DS, Hennig MS, Talukder A, Lokeshwar SD, Wang J, Garcia-Roig M, Ortiz N, Yates TJ, Lopez LE, Kallifatidis G, Kramer MW, Jordan AR, Merseburger AS, Manoharan M, Soloway MS, Terris MK, Lokeshwar VB.

Br J Cancer. 2017 Nov 7;117(10):1507-1517. doi: 10.1038/bjc.2017.318. Epub 2017 Oct 3.

3.

The andean anticancer herbal product BIRM causes destabilization of androgen receptor and induces caspase-8 mediated-apoptosis in prostate cancer.

Shamaladevi N, Araki S, Lyn DA, Ayyathurai R, Gao J, Lokeshwar VB, Navarrete H, Lokeshwar BL.

Oncotarget. 2016 Dec 20;7(51):84201-84213. doi: 10.18632/oncotarget.12393.

4.

Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer.

Jordan AR, Lokeshwar SD, Lopez LE, Hennig M, Chipollini J, Yates T, Hupe MC, Merseburger AS, Shiedlin A, Cerwinka WH, Liu K, Lokeshwar VB.

Oncotarget. 2017 Apr 11;8(15):24262-24274. doi: 10.18632/oncotarget.10529.

5.

The Role of CD44 in Disease Pathophysiology and Targeted Treatment.

Jordan AR, Racine RR, Hennig MJ, Lokeshwar VB.

Front Immunol. 2015 Apr 21;6:182. doi: 10.3389/fimmu.2015.00182. eCollection 2015. Review.

6.

Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer.

Yates TJ, Lopez LE, Lokeshwar SD, Ortiz N, Kallifatidis G, Jordan A, Hoye K, Altman N, Lokeshwar VB.

J Natl Cancer Inst. 2015 Apr 13;107(7). pii: djv085. doi: 10.1093/jnci/djv085. Print 2015 Jul.

7.

Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus.

Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, Ogawa O, Karakiewicz PI, Shariat SF.

Urol Int. 2015;94(1):1-24. doi: 10.1159/000369357. Epub 2014 Dec 10. Review.

8.

Targeting hyaluronic acid family for cancer chemoprevention and therapy.

Lokeshwar VB, Mirza S, Jordan A.

Adv Cancer Res. 2014;123:35-65. doi: 10.1016/B978-0-12-800092-2.00002-2. Review.

9.

Differential expression of SDF-1 isoforms in bladder cancer.

Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, Merseburger AS, Rosser CJ, Soloway MS, Lokeshwar VB.

J Urol. 2014 Jun;191(6):1899-1905. doi: 10.1016/j.juro.2013.11.053. Epub 2013 Nov 26.

10.

Age--an independent prognostic factor of clinical outcome in renal malignancies: results of a large study over two decades.

Hupe MC, Merseburger AS, Lokeshwar VB, Eggers H, Rott H, Wegener G, Abbas M, Kuczyk MA, Herrmann TR.

World J Urol. 2014 Feb;32(1):115-21. doi: 10.1007/s00345-013-1164-6. Epub 2013 Oct 2.

PMID:
24085371
11.

Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.

Benitez A, Yates TJ, Shamaldevi N, Bowen T, Lokeshwar VB.

J Urol. 2013 Jul;190(1):285-90. doi: 10.1016/j.juro.2012.12.011. Epub 2012 Dec 7.

12.

Wee1-Hsp90 inhibitor combination treatment: molecular therapy with potentially broad applicability.

Lokeshwar VB.

Cell Cycle. 2012 Oct 15;11(20):3722-3. doi: 10.4161/cc.22119. Epub 2012 Sep 14. No abstract available.

13.

C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer.

Yates TJ, Knapp J, Gosalbez M, Lokeshwar SD, Gomez CS, Benitez A, Ekwenna OO, Young EE, Manoharan M, Lokeshwar VB.

Cancer. 2013 Jan 1;119(1):61-71. doi: 10.1002/cncr.27661. Epub 2012 Jun 26.

14.

Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma.

Franzmann EJ, Reategui EP, Pereira LH, Pedroso F, Joseph D, Allen GO, Hamilton K, Reis I, Duncan R, Goodwin WJ, Hu JJ, Lokeshwar VB.

Head Neck. 2012 May;34(5):687-95. doi: 10.1002/hed.21810. Epub 2011 Jul 11.

15.

Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis.

Gahan JC, Gosalbez M, Yates T, Young EE, Escudero DO, Chi A, Garcia-Roig M, Satyanarayana R, Soloway MS, Bird VG, Lokeshwar VB.

J Urol. 2012 Mar;187(3):827-33. doi: 10.1016/j.juro.2011.10.150. Epub 2012 Jan 15.

16.

Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis.

Chi A, Shirodkar SP, Escudero DO, Ekwenna OO, Yates TJ, Ayyathurai R, Garcia-Roig M, Gahan JC, Manoharan M, Bird VG, Lokeshwar VB.

Cancer. 2012 May 1;118(9):2394-402. doi: 10.1002/cncr.26520. Epub 2011 Sep 1.

17.

Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells.

Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, Lokeshwar VB.

Cancer Res. 2011 Jun 15;71(12):4085-95. doi: 10.1158/0008-5472.CAN-10-4610. Epub 2011 May 9.

18.

Salivary markers and risk factor data: a multivariate modeling approach for head and neck squamous cell carcinoma detection.

Pereira LH, Adebisi IN, Perez A, Wiebel M, Reis I, Duncan R, Goodwin WJ, Hu JJ, Lokeshwar VB, Franzmann EJ.

Cancer Biomark. 2011;10(5):241-9.

PMID:
22699785
19.

Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis.

Kramer MW, Escudero DO, Lokeshwar SD, Golshani R, Ekwenna OO, Acosta K, Merseburger AS, Soloway M, Lokeshwar VB.

Cancer. 2011 Mar 15;117(6):1197-209. doi: 10.1002/cncr.25565. Epub 2010 Oct 19.

20.

Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.

Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N, Altman N.

Cancer Res. 2010 Apr 1;70(7):2613-23. doi: 10.1158/0008-5472.CAN-09-3185. Epub 2010 Mar 23.

21.

Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence.

Gomez CS, Gomez P, Knapp J, Jorda M, Soloway MS, Lokeshwar VB.

J Urol. 2009 Oct;182(4):1350-6. doi: 10.1016/j.juro.2009.06.070. Epub 2009 Aug 14.

22.

Potential new urinary markers in the early detection of bladder cancer.

Shirodkar SP, Lokeshwar VB.

Curr Opin Urol. 2009 Sep;19(5):488-93. doi: 10.1097/MOU.0b013e32832eb3a0. Review.

23.

[Urine-based diagnostics: an update on the Kiel Tumor Bank].

Hautmann S, Lokeshwar VB, Juenemann KP.

Urologe A. 2009 Jun;48(6):619-24. doi: 10.1007/s00120-009-1991-7. Review. German.

PMID:
19557467
24.

HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.

Kramer MW, Golshani R, Merseburger AS, Knapp J, Garcia A, Hennenlotter J, Duncan RC, Soloway MS, Jorda M, Kuczyk MA, Stenzl A, Lokeshwar VB.

Eur Urol. 2010 Jan;57(1):86-93. doi: 10.1016/j.eururo.2009.03.057. Epub 2009 Mar 31.

25.

Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter.

Lokeshwar VB, Gomez P, Kramer M, Knapp J, McCornack MA, Lopez LE, Fregien N, Dhir N, Scherer S, Klumpp DJ, Manoharan M, Soloway MS, Lokeshwar BL.

J Biol Chem. 2008 Oct 24;283(43):29215-27. doi: 10.1074/jbc.M801101200. Epub 2008 Aug 21.

26.

Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.

Caruso DJ, Carmack AJ, Lokeshwar VB, Duncan RC, Soloway MS, Lokeshwar BL.

Clin Cancer Res. 2008 Jul 1;14(13):4111-8. doi: 10.1158/1078-0432.CCR-08-0738.

27.

Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Shirodkar SP, Lokeshwar VB.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1111-23. doi: 10.1586/14737140.8.7.1111. Review.

28.

Hyaluronan and hyaluronidase in genitourinary tumors.

Simpson MA, Lokeshwar VB.

Front Biosci. 2008 May 1;13:5664-80. Review.

29.

Hyalurondiase: both a tumor promoter and suppressor.

Lokeshwar VB, Selzer MG.

Semin Cancer Biol. 2008 Aug;18(4):281-7. doi: 10.1016/j.semcancer.2008.03.008. Epub 2008 Mar 26. Review.

30.

Molecular risk assessment for breast cancer development in patients with ductal hyperplasias.

Poola I, Abraham J, Marshalleck JJ, Yue Q, Lokeshwar VB, Bonney G, Dewitty RL.

Clin Cancer Res. 2008 Feb 15;14(4):1274-80. doi: 10.1158/1078-0432.CCR-07-4053.

31.

Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.

Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar VB.

Cancer Res. 2008 Jan 15;68(2):483-91. doi: 10.1158/0008-5472.CAN-07-2140.

32.

Bladder cancer biomarkers: current developments and future implementation.

Alvarez A, Lokeshwar VB.

Curr Opin Urol. 2007 Sep;17(5):341-6. Review.

PMID:
17762628
33.

Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.

Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL.

Cancer Res. 2007 Jul 15;67(14):6854-62.

34.

HAS1 expression in bladder cancer and its relation to urinary HA test.

Golshani R, Hautmann SH, Estrella V, Cohen BL, Kyle CC, Manoharan M, Jorda M, Soloway MS, Lokeshwar VB.

Int J Cancer. 2007 Apr 15;120(8):1712-20.

35.

HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer.

Lokeshwar VB, Estrella V, Lopez L, Kramer M, Gomez P, Soloway MS, Lokeshwar BL.

Cancer Res. 2006 Dec 1;66(23):11219-27.

36.

Urinary bladder tumor markers.

Lokeshwar VB, Selzer MG.

Urol Oncol. 2006 Nov-Dec;24(6):528-37. Review.

PMID:
17138134
37.

Are there molecular signatures for predicting bladder cancer prognosis?

Lokeshwar VB.

J Urol. 2006 Dec;176(6 Pt 1):2347-8. No abstract available.

PMID:
17085098
38.

Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity.

Lokeshwar VB, Selzer MG, Unwala DJ, Estrella V, Gomez MF, Golshani R, Kester RR, Klumpp DJ, Gousse AE.

J Urol. 2006 Sep;176(3):1001-7.

PMID:
16890679
39.

Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.

Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, Lokeshwar VB, Lokeshwar BL.

Int J Cancer. 2006 Sep 1;119(5):1082-7.

40.

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB.

Urology. 2005 Dec;66(6 Suppl 1):64-74.

PMID:
16399416
41.

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ.

Urology. 2005 Dec;66(6 Suppl 1):35-63.

PMID:
16399415
42.

Differential selectivity of hyaluronidase inhibitors toward acidic and basic hyaluronidases.

Isoyama T, Thwaites D, Selzer MG, Carey RI, Barbucci R, Lokeshwar VB.

Glycobiology. 2006 Jan;16(1):11-21. Epub 2005 Sep 15.

PMID:
16166602
43.

HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor.

Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL.

Cancer Res. 2005 Sep 1;65(17):7782-9.

44.

Urinary uronate and sulfated glycosaminoglycan levels: markers for interstitial cystitis severity.

Lokeshwar VB, Selzer MG, Cerwinka WH, Gomez MF, Kester RR, Bejany DE, Gousse AE.

J Urol. 2005 Jul;174(1):344-9.

PMID:
15947687
45.

HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion.

Lokeshwar VB, Cerwinka WH, Lokeshwar BL.

Cancer Res. 2005 Mar 15;65(6):2243-50.

46.

Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.

Hautmann S, Toma M, Lorenzo Gomez MF, Friedrich MG, Jaekel T, Michl U, Schroeder GL, Huland H, Juenemann KP, Lokeshwar VB.

Eur Urol. 2004 Oct;46(4):466-71.

PMID:
15363562
47.

Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.

Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS, Lokeshwar VB.

Int J Cancer. 2004 Oct 20;112(1):121-9.

48.

Current bladder cancer tests: unnecessary or beneficial?

Simon MA, Lokeshwar VB, Soloway MS.

Crit Rev Oncol Hematol. 2003 Aug;47(2):91-107. Review.

PMID:
12900004
49.

Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors.

Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, Lokeshwar VB.

Int J Cancer. 2003 Sep 1;106(3):438-45.

50.

Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer.

Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, Lokeshwar VB.

Cancer Res. 2003 May 15;63(10):2638-44.

Supplemental Content

Loading ...
Support Center